ELTX vs SRG
ELTX: Elicio Therapeutics is developing lymph node-targeted, off-the-shelf immunotherapies for mKRAS-driven solid tumors using its proprietary AMP technology platform. SRG: Seritage Growth Properties is an asset-monetization vehicle currently liquidating its remaining portfolio of retail and mixed-use real estate assets to distribute proceeds to shareholders.
Side-by-side fundamentals
| Metric | ELTX | SRG | Edge |
|---|---|---|---|
| Price as of 2026-09-09 close | $2.18 | $1.91 | |
| Market cap as of 2026-09-03 | $42M | $128M | |
| Net margin | -1225.9% | -374.7% | SRG higher |
| Operating margin FY2022, SEC XBRL | -1031.4% | n/a | |
| ROE FY2025, SEC XBRL | -2418.8% | -20.6% | SRG higher |
| ROA FY2025, SEC XBRL | -153.0% | -17.3% | SRG higher |
| Debt / equity as of 2026-09-03 | 5.75 | 0.16 | SRG lower |
| Revenue growth (YoY) as of 2026-09-03 | -91.9% | -4.8% | SRG higher |
| Revenue CAGR (3y) SEC XBRL | -10.6% | -44.6% | ELTX higher |
| Dividend yield as of 2026-09-02 | n/a | +3.8% | |
| Dividend streak (yrs) SEC XBRL | 0 | 1 | SRG higher |
| Beta as of 2026-09-03 | 0.41 | 0.94 | |
| 1-year return as of 2026-09-09 close | -81.2% | -57.4% | SRG higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-09-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.